Buy Now
Anemia Drugs Market Size, Share, Growth & Industry Analysis, By Type (Sickle Cell Anemia, Plastic Anemia, Iron-deficiency Anemia), By Therapy Type (Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy), By End User (Clinic, Healthcare, Home Healthcare), and Regional Analysis, 2024-2031
Pages: 180 | Base Year: 2023 | Release: April 2025 | Author: Versha V.
The market encompasses the research, development, production, and distribution of pharmaceutical therapies for the treatment and management of anemia, a hematological disorder characterized by insufficient red blood cell or hemoglobin levels.
This market includes various drug classes, such as iron supplements, erythropoiesis-stimulating agents (ESAs), vitamin & mineral formulations, and advanced biologics designed to enhance erythropoiesis and oxygen transport.
The report presents a comprehensive analysis of the key market drivers, emerging trends, and the competitive landscape, which are expected to determine the growth dynamics throughout the forecast period.
The global anemia drugs market size was valued at USD 11.22 billion in 2023 and is projected to grow from USD 12.25 billion in 2024 to USD 23.74 billion by 2031, exhibiting a CAGR of 9.91% during the forecast period.
This market is registering significant growth, due to the increasing prevalence of anemia globally, particularly among individuals with chronic diseases such as Chronic Kidney Disease (CKD), cancer, and gastrointestinal disorders.
Growing awareness of anemia management, progress in pharmaceutical formulations, and the emergence of novel biologic therapies are expected to accelerate market expansion.
Major companies operating in the anemia drugs industry are Amgen Inc., Torrent Pharmaceuticals Ltd., AbbVie Inc., Sanofi, GSK plc, Akebia Therapeutics, Cipla Limited, Lilly USA, LLC, PHARMACOSMOS A/S, bluebird bio, Inc., Biocon, Takeda Pharmaceutical Company Limited, REGEN BIOPHARMA, INC., Pieris Pharmaceuticals, Inc, and Sun Pharmaceutical Industries Ltd.
The expanding geriatric population, which is more susceptible to anemia, along with improved access to healthcare services and innovative treatment modalities, is anticipated to drive the demand for anemia drugs.
North America dominates the market with advanced healthcare infrastructure and high adoption of novel therapies, while the market in Asia-Pacific is poised for significant growth due to rising healthcare investments, increasing disposable incomes, and a growing anemia burden.
Market Driver
"Increasing Global Burden of Anemia"
Anemia represents a significant global health concern, impacting millions of individuals across diverse demographic groups, with particularly high prevalence among children, pregnant women, and the elderly.
The condition is frequently linked to chronic illnesses such as CKD, cancer, and gastrointestinal disorders, as well as deficiencies in essential nutrients, including iron, vitamin B12, and folic acid.
Furthermore, the increasing prevalence of lifestyle-related disorders, such as diabetes and obesity, has exacerbated the incidence of anemia. Socioeconomic factors, food insecurity, and insufficient awareness of preventive healthcare further contribute to the condition’s widespread impact.
Market Challenge
"Adverse Effects of Anemia Medications"
Anemia treatments often cause significant side effects, impacting patient adherence and outcomes. Oral iron supplements, commonly used for iron-deficiency anemia, frequently cause gastrointestinal disturbances such as constipation, nausea, abdominal discomfort, and altered stool coloration, leading to poor compliance.
Intravenous iron formulations, while more effective for severe anemia, present risks of hypersensitivity reactions, hypotension, and anaphylaxis. Erythropoiesis-stimulating agents (ESAs), widely prescribed for anemia related to CKD and cancer, have been linked to increased risks of cardiovascular events, hypertension, and thromboembolism. Excessive iron supplementation can also result in iron overload and organ damage.
Advancements in drug formulations with improved bioavailability and reduced side effects are essential. Alternative delivery methods, such as controlled-release and transdermal therapies, can minimize adverse reactions. Personalized treatment plans tailored to patient-specific factors enhance efficacy while reducing risks.
Optimized dosage regimens and supportive therapies, including gastroprotective agents and dietary adjustments, improve tolerability. Regular monitoring of iron levels and cardiovascular markers helps prevent complications like iron overload.
Market Trend
"Increasing Demand for Oral and Intravenous Iron Therapies"
The rising prevalence of iron-deficiency anemia, particularly among patients with CKD, cancer, and gastrointestinal disorders, is driving the demand for oral and intravenous (IV) iron therapies.
Oral iron remains the first-line treatment; however, issues like poor absorption and gastrointestinal side effects have spurred the development of improved formulations. IV iron provides rapid replenishment with minimal gastrointestinal side effects for patients with severe anemia or those unable to tolerate oral therapy.
Advanced formulations like ferric carboxymaltose and iron isomaltoside enable high-dose administration while reducing infusion-related reactions, enhancing treatment effectiveness.
The increasing recognition of IV iron’s effectiveness in rapidly correcting hemoglobin levels, particularly in hospital and outpatient settings, coupled with improved accessibility in emerging markets, is accelerating the market growth.
Segmentation |
Details |
By Type |
Sickle Cell Anemia, Plastic Anemia, Iron-deficiency Anemia |
By Therapy Type |
Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy |
By End User |
Clinic, Healthcare, Home Healthcare |
By Region |
North America: U.S., Canada, Mexico |
Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe |
|
Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific |
|
Middle East & Africa: Turkey, UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa |
|
South America: Brazil, Argentina, Rest of South America |
Market Segmentation
Based on region, the market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
North America anemia drugs market share stood at around 35.66% in 2023, with a valuation of USD 4.00 billion. High growth of the market in North America is a result of the well-established healthcare infrastructure, high adoption of advanced anemia treatments, and strong presence of leading pharmaceutical companies in the region.
Additionally, supportive reimbursement policies, heightened awareness of anemia management, and the increasing incidence of chronic conditions such as CKD and cancer further drive growth.
Ongoing research and development, coupled with regulatory approvals for innovative therapies, reinforce North America’s leading position in the market.
The anemia drugs industry in Asia-Pacific is poised for significant growth at a robust CAGR of 10.46% over the forecast period. This region's rapid growth is fueled by increasing healthcare investments, improved access to medical services, and a rising prevalence of anemia, particularly in developing economies.
The growing geriatric population, higher incidence of nutritional deficiencies, and improving diagnostic capabilities in the region further fuel the market. Government initiatives to combat anemia, entry of global pharmaceutical companies, and the rising demand for cost-effective treatment solutions further support the strong growth trajectory of the market.
The anemia drugs industry is characterized by the presence of several leading pharmaceutical companies actively engaged in the research, development, and commercialization of innovative therapies. Market players are focusing on strategic collaborations, partnerships and acquisitions to strengthen their market position and expand their product portfolios.
Increasing investments in biologics, biosimilars, and advanced drug formulations are driving competition, with companies striving to enhance treatment efficacy and reduce side effects.
Moreover, the approval of novel therapies, along with an increasing number of patent expirations, is shaping market dynamics and facilitating the entry of generic drug manufacturers.
Recent Developments (M&A/Partnerships/Agreements/Product Launches)